Kymera Therapeutics (KYMR) Short Interest Ratio & Short Volume → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free KYMR Stock Alerts $38.50 +0.06 (+0.16%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Kymera Therapeutics Short Interest DataCurrent Short Volume9,700,000 sharesPrevious Short Volume9,060,000 sharesChange Vs. Previous Month+7.06%Dollar Volume Sold Short$333.58 millionShort Interest Ratio / Days to Cover14.8Last Record DateApril 15, 2024Outstanding Shares61,360,000 sharesPercentage of Shares Shorted15.81%Today's Trading Volume453,270 sharesAverage Trading Volume707,084 sharesToday's Volume Vs. Average64% Short Selling Kymera Therapeutics ? Sign up to receive the latest short interest report for Kymera Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKYMR Short Interest Over TimeKYMR Days to Cover Over TimeKYMR Percentage of Float Shorted Over Time Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Kymera Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20249,700,000 shares $333.58 million +7.1%N/A14.8 $34.39 3/31/20249,060,000 shares $364.21 million +8.8%N/A12 $40.20 3/15/20248,330,000 shares $338.03 million +1.0%N/A10.2 $40.58 2/29/20248,250,000 shares $352.28 million -1.8%N/A9 $42.70 2/15/20248,400,000 shares $314.33 million +1.7%N/A9.4 $37.42 1/31/20248,260,000 shares $270.76 million -4.2%N/A8.9 $32.78 Get the Latest News and Ratings for KYMR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20248,620,000 shares $242.39 million -4.9%N/A9.3 $28.12 12/31/20239,060,000 shares $230.67 million +4.4%N/A9.4 $25.46 12/15/20238,680,000 shares $226.37 million +12.9%N/A9.9 $26.08 11/30/20237,690,000 shares $159.64 million +3.2%N/A10.3 $20.76 11/15/20237,450,000 shares $134.77 million -8.0%N/A11.2 $18.09 10/31/20238,100,000 shares $94.53 million +10.7%N/A13.9 $11.67 10/15/20237,320,000 shares $92.31 million +0.4%N/A14.2 $12.61 9/30/20237,290,000 shares $101.33 million -1.8%N/A17.9 $13.90 9/15/20237,420,000 shares $141.35 million +3.6%N/A19.7 $19.05 8/31/20237,160,000 shares $136.61 million -2.3%N/A17.1 $19.08 8/15/20237,330,000 shares $143.74 million -3.9%N/A15.5 $19.61 7/31/20237,630,000 shares $166.94 million -5.5%N/A15.3 $21.88 7/15/20238,070,000 shares $178.67 million -0.6%N/A15.5 $22.14 6/30/20238,120,000 shares $186.68 million -2.3%N/A15.2 $22.99 6/15/20238,310,000 shares $229.94 million -10.1%N/A15.5 $27.67 5/31/20239,240,000 shares $272.03 million -2.0%N/A18.8 $29.44 5/15/20239,430,000 shares $281.96 million -2.0%21.3%20.8 $29.90 4/30/20239,620,000 shares $303.41 million -0.2%21.7%21.4 $31.54 4/15/20239,640,000 shares $316.77 million +0.5%21.8%21.4 $32.86 3/31/20239,590,000 shares $284.15 million +2.0%21.7%18.6 $29.63 3/15/20239,400,000 shares $292.62 million -0.6%21.3%17.6 $31.13 2/28/20239,460,000 shares $296.85 million -0.7%21.4%13.2 $31.38 2/15/20239,530,000 shares $314.49 million -1.1%21.7%13.1 $33.00 1/31/20239,640,000 shares $360.34 million +2.4%21.9%12.9 $37.38 1/15/20239,410,000 shares $325.02 million +4.6%21.4%12.3 $34.54 12/30/20229,000,000 shares $224.64 million +11.8%20.5%11.7 $24.96 12/15/20228,050,000 shares $224.60 million +9.8%18.4%10.6 $27.90 11/30/20227,330,000 shares $212.42 million -7.0%16.9%11.7 $28.98 11/15/20227,880,000 shares $236.64 million -5.6%18.1%12.3 $30.03 10/31/20228,350,000 shares $253.34 million +8.4%19.3%12.6 $30.34 10/15/20227,700,000 shares $169.40 million +1.9%18.0%11.6 $22.00 9/30/20227,560,000 shares $164.58 million +10.2%17.9%11.7 $21.77 9/15/20226,860,000 shares $197.29 million +7.7%16.2%9.9 $28.76 8/31/20226,370,000 shares $180.08 million +7.4%15.1%8.9 $28.27The Weight Loss Pill That Could Disrupt a $32 Billion Industry (Ad)A revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> KYMR Short Interest - Frequently Asked Questions What is Kymera Therapeutics' current short interest? Short interest is the volume of Kymera Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 9,700,000 shares of KYMR short. Learn More on Kymera Therapeutics' current short interest. What is a good short interest ratio for Kymera Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KYMR shares currently have a short interest ratio of 15.0. Learn More on Kymera Therapeutics's short interest ratio. Is Kymera Therapeutics' short interest increasing or decreasing? Kymera Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 9,700,000 shares, an increase of 7.1% from the previous total of 9,060,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kymera Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Kymera Therapeutics: Vericel Co. (9.36%), Denali Therapeutics Inc. (8.33%), Apogee Therapeutics, Inc. (12.97%), Sana Biotechnology, Inc. (21.81%), Twist Bioscience Co. (21.04%), Recursion Pharmaceuticals, Inc. (26.39%), Ginkgo Bioworks Holdings, Inc. (19.74%), Arcellx, Inc. (10.13%), Beam Therapeutics Inc. (16.00%), Fusion Pharmaceuticals Inc. (5.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Kymera Therapeutics stock? Short selling KYMR is an investing strategy that aims to generate trading profit from Kymera Therapeutics as its price is falling. KYMR shares are trading down $0.16 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kymera Therapeutics? A short squeeze for Kymera Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KYMR, which in turn drives the price of the stock up even further. How often is Kymera Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KYMR, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Vericel Short Interest Data Denali Therapeutics Short Interest Data Apogee Therapeutics Short Interest Data Sana Biotechnology Short Interest Data Twist Bioscience Short Interest Data Recursion Pharmaceuticals Short Interest Data Ginkgo Bioworks Short Interest Data Arcellx Short Interest Data Beam Therapeutics Short Interest Data Fusion Pharmaceuticals Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KYMR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press